Eisai Pharmaceutical - Plenty at Stake with Anti-Alzheimer R&D Programs but Lenvima Is Key
Eisai had high hopes from breast cancer treatment Halaven (eribulin) and epilepsy treatment Fycompa (perampanel). However, neither of the two has...
251 Views
Trump Health Effect: What Is Next for the Consumer Health Industry Under Trump's Leadership?
While the US consumer health industry will remain a strong centre for investment, development and technology innovation in 2017 and is expected to...
3.2k Views
Revisiting Samsung BioLogics at This Interesting Time
I don't really intend to make any investment recommendation on BioLogics at this point. I have to admit that I'm still feeling the current price is...
248 Views
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
AML represents one of the largest hematologic cancer populations with one of the worst survival rates. Global prevalence is expected to increase at...
522 Views
2017 Asset Allocation Outlook – Part 2: Trump Reflation Euphoria to Fade?
The overwhelming investor consensus a year ago was for further EM/commodity downside amid deflation fears - this year it is a USD secular bull and...
320 Views